immuno-inflammation Nanobodies (Ablynx/Sanofi)

N/A

Report date: 2025/03/20 20:00:06

Base Information

Drug Nameimmuno-inflammation Nanobodies (Ablynx/Sanofi)
Drug Alias NameN/A
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody fragment
Mechanisms of ActionImmunomodulators
TargetsUpdating
Therapy Area/IndicationsInflammation
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryBelgiumFrance
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesAblynx Nv
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesSanofiAblynx Nv
Active IndicationsN/A
Inactive IndicationsInflammation

Other Information

ATC CodeN/A
Related LinksN/A